Loop Biotech

Democratic control of both chambers reshapes the outlook for drug pricing, Medicare for All and biopharma policy.

An advisory committee is expected, and approval remains uncertain for the one-time therapy.

The results widen Novo's early edge over Eli Lilly in the oral weight loss drug race.

The federal lawsuit alleges a coverup of safety issues tied to the company's liver disease drug.

The setback affects a form of Becker muscular dystrophy that currently lacks treatment options.

Analysts are debating the prospects of drugs designed to degrade the tough-to-reach STAT6 protein.

The company is ending development of two rare disease drugs alongside the layoffs.

The case adds to evidence that tailored mRNA vaccines may help patients with lethal cancers.

KFF urged seniors to shop carefully during open enrollment given wide variance between plans.

Compass is a frontrunner in the race for the first approved psychedelic, though competitors are close behind.

The committee changes could revive Medicare for All momentum in the new Congress.

Executives voiced conviction in the coming launch of the IgA nephropathy medicine seen as key to Vertex's future.

Sanders could use his role on PDUFA reauthorization to push drug pricing and FDA reforms.

The company reaffirmed its mRNA oncology strategy on its third-quarter earnings call.

RBC notes expanding uptake of the sickle cell gene editing therapy as investors await pipeline readouts.

NeurologyLive discusses the approval and its implications for Parkinson's treatment.

Historical data suggests sector outperformance after midterms, and analysts see Democrats focused elsewhere on drug pricing.

Pharmacy Times highlights new treatment options alongside persistent patient access hurdles.

Drugmaker leaders and some biotech startups are questioning AI's role in drug discovery.

The high-stakes clinical readout drove a sharp rally in the company's stock.

Republican losses leave RFK Jr.'s MAHA movement facing an uncertain path forward.

The guidance comes as the agency expands its cell and gene therapy regulatory framework.

Before Democrats take control, Congress must fund expiring health programs and confirm HHS nominees.

The letter from trial investigators lifted Capricor shares as regulators weigh the therapy.

Korean biotechs including Legend Biotech are presenting cell therapy data at the hematology meeting.

Federal officials aim to work with states on AI oversight and protecting doctors from AI liability.

The Hong Kong biotech's oncology candidates are gaining international interest.

The decisive defeat preserves the state's recreational cannabis industry.

A Clinical Trial Vanguard piece questions whether AI-driven pipeline growth improves success rates.

A cryptic email from the health system's CEO followed a round of layoffs two weeks earlier.

A MedPage Today opinion piece cautions that cancer vaccine progress is real but incomplete.

The strategic acquisition expands the company's clinical trial supply footprint in China.

The piece suggests U.S. pharma offers exposure to Chinese biotech innovation.

The healthcare provider is expanding preventive care offerings amid rising longevity demand.

Technologists are pursuing ways to extend brain function beyond death.

A first-person account describes paying for care differently in Malta and missing U.S. digital health tools.

The Long Island event supported families affected by rare disease.